2024年度非小细胞肺癌免疫治疗研究进展  

Progress in immunotherapy for non-small cell lung cancer in 2024

作　　者：方瑜佳 苏春霞[1] Fang Yujia;Su Chunxia(Department of Medical Oncology,Shanghai Pulmonary Hospital Affiliated to Tongji University,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《肿瘤综合治疗电子杂志》2025年第1期44-49,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金面上项目(82072568,82373320);国家重点研发计划项目(2023YFC2508601,2023YFC2508604)。

摘　　要：目前,肺癌仍是中国发病率和死亡人数最高的恶性肿瘤,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占80%以上。免疫治疗的出现改变了NSCLC的治疗格局,围手术期NSCLC的免疫治疗相关临床研究不断推陈出新。在晚期NSCLC患者免疫治疗方面,一线免疫治疗联合新方案有望进一步提高疗效,且抗体药物偶联物、双特异性抗体等新药联合方案的出现有望打破免疫治疗耐药僵局。本文旨在回顾2024年度NSCLC免疫治疗领域的临床进展。Lung cancer remains the malignant tumor with the highest incidence and mortality in China.Among them,non-small cell lung cancer(NSCLC)accounts for approximately more than 80%.The advent of immunotherapy has revolutionized the therapeutic paradigm of NSCLC.The clinical studies related to immunotherapy for NSCLC in the perioperative period are constantly evolving.Regarding the immunotherapy of advanced NSCLC patients,the first-line immune combination with new regimens is expected to further enhance the therapeutic effect and challenge the existing ones.The emergence of new drug combination regimens such as antibody-drug conjugates and bispecific antibodies after drug resistance is expected to break the stalemate of drug resistance.This article reviews the clinical progress in the field of NSCLC immunotherapy in 2024,expounds on the current problems and challenges,and explores the future development directions.

关 键 词：非小细胞肺癌 围手术期 免疫治疗 抗体药物偶联物 

分 类 号：R734.2[医药卫生—肿瘤]